Materias dentro de su búsqueda.
Mostrando 5,941 - 5,960 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.39s Limitar resultados
  1. 5941
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Inducing conformational preference of the membrane protein transporter EmrE through conservative mutations
  2. 5942
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Using Genipin to Immobilize Bone Morphogenetic Protein-2 on Zirconia Surface for Enhancing Cell Adhesion and Mineralization in Dental Implant Applications
  3. 5943
    por Her, Hsuan-Lin, Boyle, Evan, Yeo, Gene W
    Publicado 2022
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Metadensity: a background-aware python pipeline for summarizing CLIP signals on various transcriptomic sites
  4. 5944
    “…NICE recommended abemaciclib with ET as an option for the adjuvant treatment of HR-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
  5. 5945
    “…The study design permits the evaluation of the effectiveness and implementation of Health4Her to predict and facilitate uptake in breast screening services. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A Brief Intervention for Improving Alcohol Literacy and Addressing Harmful Alcohol Use Among Women Attending an Australian Breast Screening Service (Health4her): Protocol for a Hybrid Effectiveness-Implementation Trial
  6. 5946
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Effects of a Combination Economic Empowerment and Family Strengthening Intervention on Psychosocial Well-being Among Ugandan Adolescent Girls and Young Women: Analysis of a Cluster Randomized Controlled Trial (Suubi4Her)
  7. 5947
    “…CONCLUSION: Among women with ER+/HER2- breast cancer with 1–3 positive nodes, and a RS of 20-25—in contrast to the RxPONDER trial—we observed that CET was associated with an OS benefit in women regardless of age.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in ER+/HER2- breast cancer pts with 1-3 positive nodes and oncotype DX recurrence score 20 to 25: an NCDB analysis
  8. 5948
    “…PATIENTS AND METHODS: Adult patients with HER2-positive (HER2+) metastatic breast cancer (mBC) initiating treatment with T-DM1 between 1/1/2013 and 9/30/2018 were included and followed through 12/31/2018. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States
  9. 5949
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    “How can you kiss and touch this child and show affection towards her? What kind of woman are you?”: Provider perspectives on stigma towards native and ethnic minority street-connected youth in the Republic of Georgia
  10. 5950
    “…In vivo, pilot studies in a GFP:ffLuc+Her2 U87 orthoptic xenograft mouse model showed significant survival (p<0.001). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    IMMU-13. PRECLINICAL EFFICACY OF MULTI-ANTIGEN (HER2/EGFR806/B7-H3/IL13RA2) TARGETING QUAD-CAR T CELLS AGAINST DIFFUSE MIDLINE GLIOMA
  11. 5951
    “…BACKGROUND: Trastuzumab (Herceptin) has improved the outcome for patients with HER2-positive breast cancer (BC) but brain metastases (BM) remain a challenge due to poor uptake of trastuzumab into the brain. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    [(225)Ac]Ac- and [(111)In]In-DOTA-trastuzumab theranostic pair: cellular dosimetry and cytotoxicity in vitro and tumour and normal tissue uptake in vivo in NRG mice with HER2-positive human breast cancer xenografts
  12. 5952
    “…Human epidermal growth factor receptor 2 (HER2) protein, which is characterized by the amplification of ERBB2, is a molecular target for HER2-overexpressing breast cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Investigation of Tumor Heterogeneity Using Integrated Single-Cell RNA Sequence Analysis to Focus on Genes Related to Breast Cancer-, EMT-, CSC-, and Metastasis-Related Markers in Patients with HER2-Positive Breast Cancer
  13. 5953
    “…To obtain a radiobioconjugate with an affinity for HER2 receptors, polyethylene glycol chains and the monoclonal antibody trastuzumab were attached to the Au@Pd nanoparticles. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Au@(109)Pd core–shell nanoparticle conjugated to trastuzumab for the therapy of HER2+ cancers: studies on the applicability of (109)Pd/(109m)Ag in vivo generator in combined β(−) auger electron therapy
  14. 5954
    “…All patients were classified into the following categories: luminal A, luminal B, HER2 overexpression, and triple-negative subtypes. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Survival Analysis Based on Clinicopathological Data from a Single Institution: Chemotherapy Intensity Would Be Enhanced in Patients with Positive Hormone Receptors and Positive HER2 in China Who Cannot Afford the Target Therapy
  15. 5955
    “…CONCLUSIONS: Lapatinib in combination with capecitabine in Japanese HER2-positive breast cancer patients was well tolerated. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study
  16. 5956
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol
  17. 5957
    por Rice, Marlin E.
    Publicado 2015
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Terry L. Erwin: She Had a Black Eye and in Her Arm She Held a Skunk: Re-published from "American Entomologist" Vol. 61 (I) on the occasion of ZooKeys 500
  18. 5958
    “…PATIENTS AND METHODS: The HER2 FISH status of BCIRG-005/006/007 patients with breast cancers was re-evaluated according to current ASCO-CAP guidelines, which designates five different groups according to HER2 FISH ratio and average HER2 gene copy number per tumor cell: group 1 (in situ hybridization [ISH]–positive): HER2-to-chromosome 17 centromere ratio ≥ 2.0, average HER2 copies ≥ 4.0; group 2 (ISH-positive): ratio ≥ 2.0, copies < 4.0; group 3 (ISH-positive): ratio < 2.0, copies ≥ 6.0; group 4 (ISH-equivocal): ratio < 2.0, copies ≥ 4.0 and < 6.0; and group 5 (ISH-negative): ratio < 2.0, copies < 4.0. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials
  19. 5959
    “…PURPOSE: The VICTOR-1 study demonstrated that the all-oral metronomic combination of vinorelbine and capecitabine is highly active and well tolerated in hormone receptor-positive/HER2-negative patients. The VICTOR-2 study was designed to confirm these results. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study
  20. 5960
    “…These Her-2/neu-loaded T2 cells reproducibly activated and expanded out Her-2/neu-specific CD8(+) T cells to 10(7) in 8 weeks. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A hybrid of B and T lymphoblastic cell line could potentially substitute dendritic cells to efficiently expand out Her-2/neu-specific cytotoxic T lymphocytes from advanced breast cancer patients in vitro
Herramientas de búsqueda: RSS